Sendas Distribuidora (ASAI3) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Apr, 2026Executive summary
Revenue reached R$ 20.6 billion in Q1 2026, up 1.7% year-over-year, despite high family debt and -12% commodity deflation impacting food consumption and sales.
Gross margin and EBITDA margin remained stable, reflecting operational resilience and disciplined cost control.
Recurring net income rose 7% to R$ 174 million, while accounting net income pre-IFRS16 was R$ 367 million, aided by PIS/COFINS credits.
Strategic initiatives included automation, cost control, expansion into drugstores/pharmacies, private label products, and digital partnerships.
ESG progress continued, with advances in efficient operations, diversity, and social impact, and recognition in ISE B3 for the 4th year.
Financial highlights
Gross profit reached R$ 3.1 billion, with a margin of 16.7% (+0.3 p.p. vs. 1Q25), driven by price management and store maturation.
Adjusted EBITDA margin was 5.5% (pre-IFRS16), stable year-over-year; adjusted EBITDA was R$ 1.0 billion.
Net income reached BRL 367 million (1.97% of net revenue), with recurring net income up 7% to R$ 174 million.
Free cash flow over the last 12 months was R$ 2.2 billion, up 34% year-over-year.
Cash and cash equivalents totaled R$ 7.5 billion at quarter-end.
Outlook and guidance
Focus remains on deleveraging, financial discipline, and margin preservation amid ongoing market uncertainty.
Expansion plans include five new stores and scaling pharmacy operations to 25 stores by year-end.
Continued investment in digital initiatives, private label products, and financial services, with ongoing pilots and partnerships.
Inflationary trends anticipated in Q2, with price corrections likely in May and June.
Latest events from Sendas Distribuidora
- Revenue up 5.2%, EBITDA margin 5.8%, leverage at 2.56x, and free cash flow R$2.8B.ASAI3
Q4 202520 Apr 2026 - Market leader with robust growth, digital innovation, and new value-creation initiatives.ASAI3
Institutional Presentation10 Apr 2026 - Revenue and EBITDA rose as leverage improved, with over 300 stores targeted for 2024.ASAI3
Q2 20241 Feb 2026 - Revenue and EBITDA up, leverage down, and expansion and deleveraging remain priorities.ASAI3
Q3 202415 Jan 2026 - Board size cut, compensation reduced, and new poison pill triggers reflect governance reforms.ASAI3
Status Update26 Dec 2025 - Record revenue, margin gains, and lower leverage defined 2024's strong performance.ASAI3
Q4 202411 Dec 2025 - Revenue up 7.2% and net income up 60% year-over-year, with strong cash flow and lower leverage.ASAI3
Q2 202523 Nov 2025 - Revenue up 7.8%, EBITDA margin at 5.5%, and leverage improved to 3.15x in Q1 2025.ASAI3
Q1 202519 Nov 2025 - Revenue, EBITDA margin, and free cash flow rose as leverage hit a multi-year low.ASAI3
Q3 202513 Nov 2025